| Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. | |
| | |
MedLine Citation:
|
PMID: 22077618 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
5-Hydroxytryptamine 2A serotonin receptor (5-HT(2A) ) is associated with the contraction of vascular smooth muscle, platelet aggregation and thrombus formation and coronary artery spasms. Sarpogrelate hydrochloride (sarpogrelate) is a selective 5-HT(2A) antagonist and was supposed to be effective for Raynaud's phenomenon with collagen disease. Sarpogrelate has not been investigated regarding the effects, safety and quality of life (QOL) in patient with skin ulcers of collagen disease. Eleven patients with skin ulcers and systemic sclerosis (SSc) were administrated sarpogrelate p.o. three times a day for 3-6 months. The area (mean ± standard error) of skin ulcer at the pretreatment, and after 3 and 6 months of sarpogrelate intake was 2.1 ± 0.8, 0.2 ± 0.1 and 0.1 ± 0.1 mm(2) , respectively. The reduction of skin ulcer area was significant after 3 months of sarpogrelate intake. In assessment of QOL, scores of symptoms and emotions but not of functioning were significantly improved after sarpogrelate intake. The global score (mean ± SE) of Skindex-16 at pretreatment, and after 3 and 6 months of sarpogrelate intake was 31.8 ± 8.7, 23.7 ± 8.3 and 10.9 ± 4.6, respectively. The score was significantly improved after 6 months of sarpogrelate intake. There were no obvious side-effects during this study. Sarpogrelate was considered to be a useful drug to improve skin ulcers and QOL in patients with SSc. |
| | |
Authors:
|
Takashi Yoshimasu; Takaharu Ikeda; Koji Uede; Nobuo Kanazawa; Fukumi Furukawa |
Related Documents
:
|
18421538 - Polymicrobial prosthetic joint infections: risk factors and outcome. 19858538 - Early treatment with, and time receiving, first disease-modifying antirheumatic drug pr... 14603208 - Patency of autogenous and polytetrafluoroethylene upper extremity arteriovenous hemodia... 22544618 - Gastrointestinal bleeding following intravenous ibandronate administration. 17391628 - Pharmacologic treatment of peptic ulcer bleeding. 3486638 - A reappraisal of 'analgesic hip'. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-14 |
Journal Detail:
|
Title: The Journal of dermatology Volume: - ISSN: 1346-8138 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-11-14 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7600545 Medline TA: J Dermatol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
© 2011 Japanese Dermatological Association. |
Affiliation:
|
Department of Dermatology, Arida Municipal Hospital, Arida Department of Dermatology, Wakayama Medical University Department of Dermatology, Wakayama Rosai Hospital, Wakayama, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: An optimized growth factor cocktail for ovine mesenchymal stem cells.
Next Document: Patient Preferences for First-Line Oral Treatment for Mild-to-Moderate Ulcerative Colitis: A Discret...